NetworkNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT
Post# of 189
(Total Views: 116)
Posted On: 09/08/2025 3:39:26 PM
NetworkNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Reports Study Showing Comparable Accuracy Between HeartBeam System and Standard 12-Lead ECG in Detecting Arrhythmias
HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care with personalized insights, announced study results showing no significant differences in detecting atrial fibrillation, atrial flutter and sinus rhythm when its deep learning algorithms were applied to the HeartBeam System versus standard 12-lead ECGs. Data from 201 patients, presented at HRX Live 2025 in Atlanta by Dr. Joshua Lampert of Mount Sinai Heart, demonstrated high accuracy rates in both groups (94.5% HeartBeam vs. 95.5% standard 12-lead). CEO Rob Eno said the findings highlight the potential of HeartBeam’s compact, 3D device to expand advanced cardiac monitoring to settings where full 12-lead ECGs may be impractical. The company plans to use these results to support future FDA submissions.
NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://nnw.fm/BEAT
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care with personalized insights, announced study results showing no significant differences in detecting atrial fibrillation, atrial flutter and sinus rhythm when its deep learning algorithms were applied to the HeartBeam System versus standard 12-lead ECGs. Data from 201 patients, presented at HRX Live 2025 in Atlanta by Dr. Joshua Lampert of Mount Sinai Heart, demonstrated high accuracy rates in both groups (94.5% HeartBeam vs. 95.5% standard 12-lead). CEO Rob Eno said the findings highlight the potential of HeartBeam’s compact, 3D device to expand advanced cardiac monitoring to settings where full 12-lead ECGs may be impractical. The company plans to use these results to support future FDA submissions.
NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://nnw.fm/BEAT
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)